Literature DB >> 22682226

Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT.

Sandra L Ross1, Lynn Tran, Aaron Winters, Ki-Jeong Lee, Cherylene Plewa, Ian Foltz, Chadwick King, Les P Miranda, Jennifer Allen, Holger Beckman, Keegan S Cooke, Gordon Moody, Barbra J Sasu, Elizabeta Nemeth, Tomas Ganz, Graham Molineux, Tara L Arvedson.   

Abstract

Ferroportin is the primary means of cellular iron efflux and a key component of iron metabolism. Hepcidin regulates Fpn activity by inducing its internalization and degradation. The mechanism of internalization is reported to require JAK2 activation, phosphorylation of Fpn tyrosine residues 302 and 303, and initiation of transcription through STAT3 phosphorylation. These findings suggest Fpn may be a target for therapeutic intervention through JAK2 modulation. To evaluate the proposed mechanism, Fpn internalization was assessed using several techniques combined with reagents that specifically recognized cell-surface Fpn. In vitro results demonstrated that Hepc-induced Fpn internalization did not require JAK2 or phosphorylation of Fpn residues 302 and 303, nor did it induce JAK-STAT signaling. In vivo, inhibition of JAK2 had no effect on Hepc-induced hypoferremia. However, internalization was delayed by mutation of two Fpn lysine residues that may be targets of ubiquitination.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682226     DOI: 10.1016/j.cmet.2012.03.017

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  57 in total

1.  Sequestration and scavenging of iron in infection.

Authors:  Nermi L Parrow; Robert E Fleming; Michael F Minnick
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

Review 2.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

3.  Rapid removal of phagosomal ferroportin in macrophages contributes to nutritional immunity.

Authors:  Ronald S Flannagan; Tayler J Farrell; Steven M Trothen; Jimmy D Dikeakos; David E Heinrichs
Journal:  Blood Adv       Date:  2021-01-26

Review 4.  Iron overload and altered iron metabolism in ovarian cancer.

Authors:  Stephanie Rockfield; Joseph Raffel; Radhe Mehta; Nabila Rehman; Meera Nanjundan
Journal:  Biol Chem       Date:  2017-08-28       Impact factor: 3.915

5.  Fluorescence resonance energy transfer links membrane ferroportin, hephaestin but not ferroportin, amyloid precursor protein complex with iron efflux.

Authors:  Adrienne C Dlouhy; Danielle K Bailey; Brittany L Steimle; Haley V Parker; Daniel J Kosman
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

6.  Iron Loading Exaggerates the Inflammatory Response to the Toll-like Receptor 4 Ligand Lipopolysaccharide by Altering Mitochondrial Homeostasis.

Authors:  Konrad Hoeft; Donald B Bloch; Jan A Graw; Rajeev Malhotra; Fumito Ichinose; Aranya Bagchi
Journal:  Anesthesiology       Date:  2017-07       Impact factor: 7.892

Review 7.  A systems biology approach to iron metabolism.

Authors:  Julia Chifman; Reinhard Laubenbacher; Suzy V Torti
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload.

Authors:  Andrew J Schwartz; Nupur K Das; Sadeesh K Ramakrishnan; Chesta Jain; Mladen T Jurkovic; Jun Wu; Elizabeta Nemeth; Samira Lakhal-Littleton; Justin A Colacino; Yatrik M Shah
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

9.  Non-mutagenic Suppression of Enterocyte Ferroportin 1 by Chemical Ribosomal Inactivation via p38 Mitogen-activated Protein Kinase (MAPK)-mediated Regulation: EVIDENCE FOR ENVIRONMENTAL HEMOCHROMATOSIS.

Authors:  Chang-Kyu Oh; Seong-Hwan Park; Juil Kim; Yuseok Moon
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

10.  Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

Authors:  Malte Asshoff; Verena Petzer; Matthew R Warr; David Haschka; Piotr Tymoszuk; Egon Demetz; Markus Seifert; Wilfried Posch; Manfred Nairz; Pat Maciejewski; Peter Fowles; Christopher J Burns; Gregg Smith; Kay-Uwe Wagner; Guenter Weiss; J Andrew Whitney; Igor Theurl
Journal:  Blood       Date:  2017-02-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.